他克莫司结合蛋白FKBP8介导肌球蛋白轻链激酶依赖性屏障调节,是克罗恩病的潜在治疗靶点
肠屏障丢失是克罗恩病(CD)危险因素,可能与肌球蛋白轻链激酶1(MLCK1)表达及酶活性增加有关。本研究在体外、转基因与敲除肠上皮细胞系、人肠类器官及小鼠模型中证实,MLCK1与FKBP8的PPI结构域特异性结合,他克莫司可阻断该结合并逆转TNF诱导的MLCK1募集与屏障丢失;CD患者活检显示细胞间连接处MLCK1-FKBP8相互作用增多。
要点
- MLCK1与FKBP8的PPI结构域特异性结合,该结合为他克莫司所阻断。
- 敲除或显性负性FKBP8可阻止TNF诱导的MLCK1募集与体外屏障丢失。
- CD患者活检细胞间连接处MLCK1-FKBP8相互作用较对照增多。
核心结论
- 与FKBP8结合(可被他克莫司阻断)是MLCK1募集至细胞间连接及下游免疫介导屏障丢失所必需。
- CD中观察到的MLCK1活性增加、细胞连接处MLCK1定位及连接周围MLCK1-FKBP8相互作用增多提示靶向该过程可能对 human 疾病有治疗作用。
- 这些关于疾病相关屏障丢失机制的新见解为FKBP8-MLCK1相互作用的治疗开发提供了关键基础。
研究设计与样本
- 体外评估FKBP8与MLCK1的蛋白相互作用。
- 使用转基因和敲除肠上皮细胞系、人肠类器官及小鼠作为临床前模型。
- 在CD患者和对照受试者的活检中进行验证。
主要发现
- MLCK1与FKBP8的PPI结构域特异性相互作用。
- 敲除或显性负性FKBP8表达在体外阻止TNF诱导的MLCK1募集和屏障丢失。
- 他克莫司阻断MLCK1-FKBP8结合,在体外和体内逆转TNF诱导的MLCK1-FKBP8相互作用、MLCK1募集和屏障丢失。
- CD患者活检显示细胞间连接处MLCK1-FKBP8相互作用数量较对照受试者增多。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Intestinal barrier loss is a Crohn's disease (CD) risk factor. This may be related to increased expression and enzymatic activation of myosin light chain kinase 1 (MLCK1), which increases intestinal paracellular permeability and correlates with CD severity. Moreover, preclinical studies have shown that MLCK1 recruitment to cell junctions is required for tumour necrosis factor (TNF)-induced barrier loss as well as experimental inflammatory bowel disease progression. We sought to define mechanisms of MLCK1 recruitment and to target this process pharmacologically. DESIGN: Protein interactions between FK506 binding protein 8 (FKBP8) and MLCK1 were assessed in vitro. Transgenic and knockout intestinal epithelial cell lines, human intestinal organoids, and mice were used as preclinical models. Discoveries were validated in biopsies from patients with CD and control subjects. RESULTS: MLCK1 interacted specifically with the tacrolimus-binding FKBP8 PPI domain. Knockout or dominant negative FKBP8 expression prevented TNF-induced MLCK1 recruitment and barrier loss in vitro. MLCK1-FKBP8 binding was blocked by tacrolimus, which reversed TNF-induced MLCK1-FKBP8 interactions, MLCK1 recruitment and barrier loss in vitro and in vivo. Biopsies of patient with CD demonstrated increased numbers of MLCK1-FKBP8 interactions at intercellular junctions relative to control subjects. CONCLUSION: Binding to FKBP8, which can be blocked by tacrolimus, is required for MLCK1 recruitment to intercellular junctions and downstream events leading to immune-mediated barrier loss. The observed increases in MLCK1 activity, MLCK1 localisation at cell junctions and perijunctional MLCK1-FKBP8 interactions in CD suggest that targeting this process may be therapeutic in human disease. These new insights into mechanisms of disease-associated barrier loss provide a critical foundation for therapeutic exploitation of FKBP8-MLCK1 interactions.
引用
- Zuo L, Kuo WT, Cao F, et al. Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn's disease. Gut. 2022. PMID: 35537812. doi:10.1136/gutjnl-2021-326534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。